Vaxcyte, Inc. (NASDAQ:PCVX) COO Sells $669,280.00 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil sold 8,000 shares of the stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $83.66, for a total transaction of $669,280.00. Following the transaction, the chief operating officer now owns 205,695 shares in the company, valued at approximately $17,208,443.70. The trade was a 3.74 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Jim Wassil also recently made the following trade(s):

• On Monday, December 2nd, Jim Wassil sold 8,000 shares of Vaxcyte stock. The stock was sold at an average price of $92.49, for a total transaction of $739,920.00.
• On Friday, November 1st, Jim Wassil sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $106.80, for a total transaction of $854,400.00.

Vaxcyte Stock Up 1.9 %

Shares of NASDAQ PCVX opened at $84.86 on Monday. The business has a 50 day moving average price of $92.63 and a two-hundred day moving average price of $93.22. Vaxcyte, Inc. has a fifty-two week low of $53.83 and a fifty-two week high of $121.06. The firm has a market cap of $10.58 billion, a PE ratio of -18.45 and a beta of 0.98.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($1.10) by $0.27. During the same quarter last year, the business earned ($0.91) EPS. On average, analysts anticipate that Vaxcyte, Inc. will post -4.14 earnings per share for the current year.

Wall Street Analysts Forecast Growth

PCVX has been the topic of a number of research analyst reports. The Goldman Sachs Group began coverage on Vaxcyte in a report on Friday, December 20th. They issued a “buy” rating and a $135.00 target price on the stock. Mizuho boosted their target price on Vaxcyte from $113.00 to $163.00 and gave the stock an “outperform” rating in a report on Tuesday, September 10th. Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a research report on Wednesday, November 6th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $140.00 price target on shares of Vaxcyte in a research report on Wednesday, November 6th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $145.71.

Hedge Funds Weigh In On Vaxcyte

Several large investors have recently added to or reduced their stakes in the company. Everence Capital Management Inc. acquired a new stake in shares of Vaxcyte during the fourth quarter worth $301,000. Principal Financial Group Inc. raised its stake in Vaxcyte by 186.2% during the third quarter. Principal Financial Group Inc. now owns 52,702 shares of the company’s stock worth $6,022,000 after acquiring an additional 34,287 shares during the period. Lord Abbett & CO. LLC lifted its holdings in Vaxcyte by 26.9% in the third quarter. Lord Abbett & CO. LLC now owns 312,425 shares of the company’s stock worth $35,701,000 after acquiring an additional 66,183 shares during the last quarter. Franklin Resources Inc. lifted its holdings in Vaxcyte by 13.2% in the third quarter. Franklin Resources Inc. now owns 2,786,335 shares of the company’s stock worth $315,162,000 after acquiring an additional 324,560 shares during the last quarter. Finally, Sanctuary Advisors LLC acquired a new position in Vaxcyte in the third quarter valued at approximately $507,000. 96.78% of the stock is currently owned by institutional investors.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.